See more here:
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early…
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of…
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated…
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
See the article here:
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
Evn Introduces a Game-Changer in Cannabis Edibles with New Hemp-Derived Live Resin Gummies
Better Choice Company To Effectuate a Reverse Stock Split
See more here:
Better Choice Company To Effectuate a Reverse Stock Split
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD…
Ultimovacs ASA: Mandatory notification of trades by primary insider
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
Originally posted here:
CRISPR Therapeutics Announces $280 Million Registered Direct Offering